Mani Foroohar Analyst PerformanceSenior Managing Director, Genetic Medicines at Leerink PartnersMani Foroohar is a stock analyst at Leerink Partners focused in the medical sector, covering 20 publicly traded companies. Over the past year, Mani Foroohar has issued 18 stock ratings, including buy, hold, and sell recommendations. While full access to Mani Foroohar's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mani Foroohar's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings32 Last 6 YearsBuy Recommendations46.88% 15 Buy RatingsCompanies Covered20 Unique Companies Ratings Distribution32RatingsDistribution of strong buy, buy, hold, and sell ratings by Mani Foroohar.RatingPercentageCount Strong Buy0.0%0 ratings Buy46.9%15 ratings Hold31.3%10 ratings Sell21.9%7 ratingsOut of 32 total stock ratings issued by Mani Foroohar at Leerink Partners, the majority (46.9%) have been Buy recommendations, followed by 31.3% Hold and 21.9% Sell.Best & Worst CallsBest Call000.0%LXEOMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%SRPTJan 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ95.0% of companies on NASDAQ19 companiesNYSE5.0% of companies on NYSE1 companyMani Foroohar, an analyst at Leerink Partners, currently covers 20 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical16 companies80.0%Retail/Wholesale2 companies10.0%Business Services1 company5.0%Computer and Technology1 company5.0%Mani Foroohar of Leerink Partners specializes in stock coverage within the Medical sector, with additional focus on Retail/Wholesale and Business Services companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE10 companies50.0%MED - DRUGS4 companies20.0%MED - GENERIC DRG1 company5.0%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC1 company5.0%FINANCIAL TRANSACTION SERVICES1 company5.0%SEMI - GENERAL1 company5.0%RETAIL - RESTRNTS1 company5.0%INTERNET COMMERCE1 company5.0% About Mani ForooharMani Foroohar, M.D., is a Senior Research Analyst within our Therapeutics team focusing on Genetic Medicines. Mani joined Leerink Partners from Aptigon Capital, a Citadel Company, where he most recently was a Therapeutics Analyst focused on U.S. and EU biotechnology, major pharmaceuticals and specialty pharmaceuticals sectors. Prior to Aptigon, he was an Analyst at Green Owl Capital Management and an Assistant Vice President of Equity Research at Barclays. In 2013, Mani co-founded Cellanyx Diagnostics, a company developing a proprietary live tumor cell, phenotypic platform for precision risk stratification in cancer to inform clinical treatment decision-making. He holds an M.D. from Stanford, where he was a Howard Hughes Medical Institute Research Fellow in the Department of Genetics, an M.B.A. from Columbia, and a B.S. from UCLA.Follow on LinkedIn Mani Foroohar's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCAMPCAMP4 Therapeutics4/2/2026Boost Price Target$4.51$9.00Outperform$0.0000.00% ROITNYATenaya Therapeutics3/12/2026Reiterated Rating$0.91$2.00Outperform$0.0000.00% ROIBBIOBridgeBio Pharma3/12/2026Reiterated Rating$68.37$98.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics3/3/2026Boost Price Target$13.80$29.00Outperform$0.0000.00% ROIIONSIonis Pharmaceuticals3/3/2026Boost Price Target$79.04$104.00Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals2/26/2026Lower Price Target$92.71$118.00Outperform$0.0000.00% ROIMRNAModerna1/30/2026Reiterated Rating$46.86Underperform$0.0000.00% ROIIONSIonis Pharmaceuticals12/15/2025Boost Price Target$80.64$100.00Outperform$0.0000.00% ROIRGNXREGENXBIO12/15/2025Boost Price Target$13.87$20.00Outperform$0.0000.00% ROIBBIOBridgeBio Pharma12/15/2025Boost Price Target$74.71$86.00Outperform$0.0000.00% ROIALNYAlnylam Pharmaceuticals12/15/2025Lower Price Target$391.15$351.00Market Perform$0.0000.00% ROIMRNAModerna11/21/2025Boost Price Target$22.90$18.00Underperform$0.0000.00% ROIFDMT4D Molecular Therapeutics10/31/2025Reiterated Rating$11.69$17.00Outperform$0.0000.00% ROIBBIOBridgeBio Pharma10/27/2025Set Price Target$63.57$68.00Outperform$0.0000.00% ROILXEOLexeo Therapeutics10/7/2025Boost Price Target$8.48$20.00Outperform$0.0000.00% ROIRCKTRocket Pharmaceuticals10/3/2025Lower Price Target$3.20$7.00Market Perform$0.0000.00% ROIMRNAModerna8/22/2025Lower Price Target$27.61$15.00Underperform$0.0000.00% ROIRCKTRocket Pharmaceuticals5/28/2025Reiterated Rating$2.33$8.00Market Perform$0.0000.00% ROILXEOLexeo Therapeutics3/24/2025Lower Price Target$3.44$18.00Outperform$0.0000.00% ROIRXRXRecursion Pharmaceuticals2/28/2025Lower Price Target$7.51$6.00Market Perform$0.0000.00% ROIFDMT4D Molecular Therapeutics1/13/2025Lower Price Target$4.80$27.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupMorgan StanleyRoyal Bank Of CanadaJefferies Financial GroupThe Goldman Sachs GroupStifel NicolausRaymond James FinancialMizuhoBank of AmericaKeyCorpSanford C. BernsteinWolfe ResearchCICC Research Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
